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Abstract
We aimed to evaluate the utility of a simplified ultrasonography (US) scoring system, which is desired in daily clinical practice, among
patients with rheumatoid arthritis (RA) receiving biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDs).
A total of 289 Japanese patients with RA who were started on tumor necrosis factor inhibitors, abatacept, tocilizumab, or Janus
kinase inhibitors between June 2013 and April 2019 at one of the 15 participating rheumatology centers were reviewed. We
performed US assessment of articular synovia over 22 joints among bilateral wrist and finger joints, and the 22-joint (22j)-GS and 22-
joint (22j)-PD scores were evaluated as an indicator of US activity using the sum of the GS and PD scores, respectively.
The top 6 most affected joints included the bilateral wrist and second/third metacarpophalangeal joints. Therefore, 6-joint (6j)-GS
and -PD scores were defined as the sum of the GS and PD scores from the 6 synovial sites over the aforementioned 6 joints,
respectively. Although the 22j- or 6j-US scores were significantly correlated with DAS28-ESR or -CRP scores, the correlations were
weak. Conversely, 6j-US scores were significantly and strongly correlated with 22j-US scores not only at baseline but also after
therapy initiation.
Using a multicenter cohort data, our results indicated that a simplified US scoring system could be adequately tolerated during any
disease course among patients with RA receiving biological/targeted synthetic DMARDs.
Abbreviations: CRP = C-reactive protein, DMARD = disease-modifying antirheumatic drugs, ESR = erythrocyte sedimentation
rate, GS = Grayscale, PD = Power Doppler, RA = rheumatoid arthritis, US = ultrasonography.
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Ultrasonography (US) is a noninvasive and valuable imaging tool
comparable to but more accessible than magnetic resonance
imaging (MRI) for joint assessment among patients with
rheumatoid arthritis (RA).[1] Among the different imaging tools
described in the European League Against Rheumatism[2]
recommendations, US is especially helpful for the following
various situations encountered during daily clinical practice:
diagnosis of RA, evaluation of disease activity/treatment
response/prognosis, and support of remission surveillance.[3]
Experts have recommended that patients with RA receiving
disease-modifying antirheumatic drugs (DMARDs) undergo
joint assessment using UA at baseline and after 3 to 6 months
to assess the initial response to each therapy[4] based on the treat-
to-target (T2T) strategy of RA.[5] However, with increasing US
assessment opportunities for the tight management of RA, a more
simplified US assessment strategy that maintains accuracy is
desired in daily clinical practice.
The original US scoring system of RA had been developed by
Naredo et al[6] who had conducted US assessment on 12 joints
(bilateral elbow, wrist, second/third metacarpophalangeal, knee,
and ankle joints). In addition, our previous study suggested that
simplified US assessment including 6 synovial sites over 6 joints
(bilateral wrist and second/third metacarpophalangeal joints), as
well as US assessment, including 24 synovial sites over 12 joints,
reflected clinical disease activity and serum angiogenic factors.[7]
However, few studies have evaluated the utility of a simplified US
scoring system by consecutive US assessments at multicenters.
Using a multicenter US cohort data, the present study thus
consecutively evaluated the utility of a simplified US scoring
system involving 6 limited synovial sites among patients with RA
receiving biological/targeted synthetic DMARDs.
2. Methods
2.1. Study design
This study is part of an ongoing nonrandomized, multicenter,
prospective cohort study of patients with active RA who received
biological or targeted DMARD therapy at 15 participating
rheumatology centers within the Kyushu region of Japan since
June 2013. Here, we evaluate clinical disease activity and US
findings every 3 months for a year starting from the initiation of
new biological or targeted synthetic DMARDs.
The study is registered with the University Hospital Medical
Information Network Clinical Trials Registry (http://www.umin.
ac.jp/ctr/, #UMIN000012524) and was approved by the
Institutional Review Board of Nagasaki University (Approval
No. 13102866). All patients gave their signed informed consent
to participate in accordance with the Helsinki declaration.
2.2. Patients
A total of 289 Japanese patients with RA who were started on
tumor necrosis factor inhibitors (e.g., infliximab, adalimumab,
etanercept, certolizumab pegol, and golimumab), abatacept,
tocilizumab, or Janus kinase inhibitors (e.g., tofacitinib and
baricitinib) between June 2013 and April 2019 at one of the 15
participating rheumatology centers were reviewed. All patients
were required to satisfy the 1987 American College of Rheuma-
tology and/or the 2010 American College of Rheumatology/
European League Against Rheumatism criteria for RA.[8,9]
Biological/targeted synthetic DMARD dosages were adminis-
tered as recommended by the manufacturers: infliximab
(3–10mg/kg via intravenous infusion every 8 weeks or 3–6mg/
kg via intravenous infusion every 4 weeks), adalimumab (40mg
via subcutaneous injection every 2 weeks), etanercept (50mg via
subcutaneous injection weekly), certolizumab pegol (400mg via
subcutaneous injection every 4 weeks), golimumab (50 or 100mg
via subcutaneous injection every 4 weeks), abatacept (125mg via
subcutaneous injection weekly or 500–750mg via intravenous
infusion every 4 weeks), tocilizumab (162mg via subcutaneous
injection every 2 weeks or 8mg/kg via intravenous infusion every
4 weeks), tofacitinib (5–10mg via daily oral administration), and
baricitinib (2–4mg via daily oral administration).
2.3. Clinical disease activity assessment
The clinical disease activity of RA in each patient was evaluated
using the Disease Activity Score 28 (DAS28) based on erythrocyte
sedimentation rate (ESR) or C-reactive protein (CRP) at baseline
and 6 and 12 months after therapy initiation.
2.4. US assessment
At baseline and 6 and 12 months after therapy initiation,
sonographers registered by the Japan College of Rheumatology
(not the attending physicians) performed US assessment of
articular synovia over 22 joints. Examination sites included
bilateral wrist and first to fifth metacarpophalangeal and
proximal interphalangeal joints. Systematic multiplanar gray-
scale (GS) and power Doppler (PD) joint examinations were
performed using a multifrequency linear transducer (12–18.5
MHz) and one of the following scanners: Toshiba AplioXG or
Aplio300, GE Logic series 7 or 8 or HITACHI HI VISIONAvius,
andNoblus or HI VISION Preirus. Each joint was given a GS and
PD score from 0 to 3 in a semi-quantitative manner. Thereafter,
the 22-joint (22j)-GS and -PD scores, which were collectively
referred to as the 22j-US scores, were evaluated as an indicator of
US activity using the sum of the GS and PD scores, respective-
ly.[10] Interobserver reliability was confirmed in a previous
investigation.[11]
Among the bilateral wrist and finger joints frequently affected
by RA, the 6-joint (6j)-GS and 6j-PD scores, which were
collectively referred to as the 6j-US scores, were evaluated using
the sum of the GS and PD scores from 6 synovial sites over the top
6 most affected joints, respectively.t
2.5. Statistical analyses
Missing data for disease activity indicators at 6 or 12 months due
to discontinuation of biological or targeted synthetic DMARDs
were treated as missing values. Categorical variables were
described as frequencies and quantitative variables as medians
and interquartile ranges. Within-group comparisons were made
using the Mann–Whitney U test. Correlations were assessed
using Spearman correlation coefficient. All statistical analyses
were performed using JMP pro 14.0 software (SAS Institute,
Cary, NC).
The effect of each visit (at baseline and 6 and 12months) on the
correlation between 22j-US scores (including 22j-GS and -PD
scores) and 6j-US scores (including 6j-GS and -PD scores) was
examined using the following procedure with R software (ver.
3.2.3). Initially, regression lines of the 22j-US scores on the 6j-US
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scores were estimated for each visit. Thereafter, the difference
between each visit was determined using the sum of squared
residuals. These 2 steps were iterated using visit-randomized
data between baseline and 6 months and between baseline and
12 months until 500 comparisons were obtained. Finally, the
probability distribution of the difference under the null
hypothesis was estimated from the empirical distribution
obtained from the 500 visit-randomized datasets for each
comparison. The P value was obtained as a quantile of the
difference in the original dataset under the null hypothesis
distribution. The effect of each visit on the correlation between
DAS28-ESR and 22j-US scores and between DAS28-ESR and 6j-
US scores were also examined using methods similar to those
described above.
A P value of <.05 (2-tailed) was considered statistically
significant for all analyses. GraphPad Prism version 7.0 was used
to create the figure.
3. Results
3.1. Patient characteristics
Demographic and clinical characteristics of the 289 patients
with RA enrolled herein are presented (see Supplementary
Table, http://links.lww.com/MD/F339). Accordingly, the medi-
an (interquartile range) age and disease duration was 66.0
(56.0–74.0) years and 52.0 (12.0–131.0) months, respectively.
Moreover, 58.8% and 52.6% of the patients received
concomitant methotrexate and low-dose oral glucocorticoids,
respectively, while 35.3% had a history of biological/targeted
synthetic DMARD use. Tumor necrosis factor inhibitors were
introduced in 105 patients (infliximab, 22; adalimumab, 21;
etanercept, 19; certolizumab pegol, 19; golimumab, 24),
abatacept in 93, tocilizumab in 69, tofacitinib in 9, and
baricitinib in 13 patients.
3.2. The top 6 most affected joints
Figure 1A and B show the sum total of baseline GS and PD score
of the 289 patients with enrolled RA at each joint, respectively.
The top 6 most affected joints included the bilateral wrist and
second/third metacarpophalangeal joints in either point of view
of the sum total of GS or PD score. Therefore, 6j-GS and -PD
scores were defined as the sum of the GS and PD scores from the 6
synovial sites over the aforementioned 6 joints, respectively.
3.3. Changes in DAS28, 22-joint US scores, and 6-joint US
scores
Data for 239 and 194 patients were obtained at 6 and 12months,
respectively. Accordingly, all data regarding disease activity
indicators, namely DAS28, 22j-GS and 22j-PD scores, and the 6j-
GS and 6j-PD scores improved with time after therapy initiation
(see Supplementary Figure, http://links.lww.com/MD/F338).
3.4. Correlations among DAS28, 22-joint US scores, and
6-joint US scores
Correlations between clinical disease activity and US scores are
presented in Table 1. Although both DAS28-ESR and DAS28-
CRP scores were significantly positively correlated with the 22j-
GS, 22j-PD, 6j-GS, and 6j-PD scores, such correlations tended to
weaken with time after therapy initiation. 6j-GS and 6j-PD scores
were strongly correlated with 22j-GS and 22j-PD scores,
respectively. Moreover, such correlations tended to become
extremely strong with time after therapy initiation.
3.5. The effect of each visit on the correlation among
DAS28, 22-joint US scores, and 6-joint US scores
Figure 2 shows the regression lines of the 22j-GS and 22j-PD
scores on the 6j-GS and 6j-PD scores for each visit, respectively
Figure 1. The sum total of baseline GS and PD score of patients with enrolled RA at each joint. (A) The sum total of baseline GS score of patients with enrolled RA at
each joint; 482 and 438 at the wrist, 199 and 172 at the 1st MCP, 353 and 274 at the 2nd MCP, 254 and 222 at the 3rd MCP, 160 and 132 at the 4th MCP, 163 and
123 at the 5thMCP, 166 and 96 at the 1st PIP, 151 and 92 at the 2nd PIP, 163 and 107 at the 3rd PIP, 106 and 99 at the 4th PIP, and 92 and 66 at the 5th PIP joint each
in the order of right and left side. (B) The sum total of baseline PD score of patients with enrolled RA at each joint; 392 and 355 at the wrist, 115 and 98 at the 1st
MCP, 214 and 191 at the 2ndMCP, 160 and 146 at the 3rd MCP, 96 and 79 at the 4th MCP, 91 and 66 at the 5th MCP, 92 and 46 at the 1st PIP, 107 and 58 at the 2nd
PIP, 97 and 68 at the 3rd PIP, 55 and 57 at the 4th PIP, and 41 and 32 at the 5th PIP joint each in the order of right and left side. GS = Grayscale, MCP =
metacarpophalangeal, PD = power Doppler, PIP = proximal interphalangeal.
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(Fig. 2A,B). The effect of each visit on the correlation between the
22j-US and 6j-US scores was then evaluated using visit-
randomized data between baseline and 6 months and between
baseline and 12 months. The visitation at 6 and 12 months had a
significantly greater effect on the correlation between 22j-US and
6j-US scores compared with that at baseline (not shown, P< .05
for all).
Figure 3 shows the regression lines of the DAS28-ESR on the
22j-GS and 22j-PD scores and on the 6j-GS and 6j-PD scores for
each visit (Fig. 3A–D). The visitation at 6 and 12 months had no
significant effect on the correlation between DAS28-ESR and 22j-
US scores and between DAS28-ESR and 6j-US scores (not shown,
P> .05 for all).
4. Discussion
Although many previous studies have shown the utility of a
simplified US assessment in daily practice,[12–16] those studies
have mentioned about patients with RA receiving conventional
synthetic DMARDs or limited biological DMARDs such as
antitumor necrosis factor inhibitors at single center. To the best of
our knowledge, this has been the first report to evaluate the utility
of a simplified US scoring system at consecutive points among
patients with RA receiving whole kinds of biological/targeted
synthetic DMARDs at multicenters. Although both 22j-US and
6j-US scores were significantly correlated with DAS28-ESR or
-CRP scores, such correlations were weak. Conversely, 6j-US
scores were significantly correlated with 22j-US scores at baseline
and even stronger after therapy initiation.
Studies have shown that there is discordance between both
clinical and US evaluations and that subclinical synovitis detected
by US is a risk factor for flares and further bone destruction even
in clinical remission.[17,18] The present study showed a significant
albeit weak correlation between DAS28 and both 22j-US and 6j-
US scores not only at baseline but also after therapy initiation.
Given the weak correlation between clinical and US evaluations,
patients with RA would be recommended to undergo objective
joint assessment using US, in addition to clinical assessment, after
the initiation of a new therapy.
With the increased importance of US assessment, a more
efficient and simplified US scoring system has been desired in
daily clinical practice. Previous reports by Naredo et al[6] for UA
and OMERACT for MRI[19] have shown that second/third
metacarpophalangeal joints are considered important areas for
Figure 2. Regression lines between 22-joint and 6-joint US scores. The regression lines of the 22j-GS and -PD scores on the 6j-GS and 6j-PD scores for baseline
and 6 months (A) and for baseline and 12 months (B) are shown. GS = Grayscale, PD = power Doppler, US = ultrasonography.
Table 1
Correlations among disease activity, 22 joints US scores, and 6 joints US scores at baseline and at 6 and 12 months.
DAS28-ESR DAS28-CRP 22 joints-GS scores 22 joints-PD scores




22 joints-PD scores 0.45†0.35†0.29† 0.45†0.43†0.34†





6 joints-PD scores 0.38†, 0.36†, 0.30† 0.38†, 0.44†, 0.32† 0.85†0.94†0.96†
Correlations between 2 variables are shown at baseline and at 6 and 12 mo in the order. Correlations were assessed with Spearman correlation coefficient test.
CRP = C-reactive protein, DAS28 = disease activity score 28, ESR = erythrocyte sedimentation rate, GS = grey-scale, PD = power Doppler.
∗
P< .001, †P< .0001.
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radiographic imaging of RA. The present study showed that the
bilateral wrist and second/third metacarpophalangeal joints were
the most frequently affected joints among patients with RA and
that 6j-US scores were significantly and strongly correlated with
22j-US scores both before and after the initiation of a new
therapy. Our results suggested that a simplified US scoring system
involving 6 synovial sites over 6 joints could be adequately
tolerated during any disease course among patients with RA.
From our results in a multicenter cohort, a simplified US scoring
system may be widely tolerated in multicenter clinical trials, for
example, as an indicator of US activity.
Our study has several limitations. A limitation of the present
study was that the simplified US scoring system was defined using
bilateral wrist and second/third metacarpophalangeal joints,
which are frequently affected by RA. The present study is limited
by US assessments eliminating the possible involvement of the
joints other than bilateral wrist and finger joints. This simplified
US scoring system may be ineffective in assessing the initial
response to each therapy among patients who have no PD signal
in the aforementioned six joints upon initiation of a new therapy.
Second, the mode of action of tumor necrosis factor inhibitors,
abatacept, tocilizumab, and Janus kinase inhibitors are different.
However, we could not evaluate the utility of a simplified US
scoring system for each treatment due to a small sample of each
treatment. The utility of a simplified US scoring system should be
distinctively evaluated by further increasing the number of
subjects.
In conclusion, our results indicated that a simplified US scoring
system involving 6 synovial sites over the bilateral wrist and
second/third metacarpophalangeal joints could be adequately
Figure 3. Regression lines between DAS28-ESR and US scores. The regression lines of the DAS28-ESR on the 22j-GS and -PD scores for baseline and 6 months
(A) and for baseline and 12 months (B) are shown. The regression lines of the DAS28-ESR on the 6j-GS and -PD scores for baseline and 6 months (C) and for
baseline and 12 months (D) are shown. ESR = erythrocyte sedimentation rate, GS = Grayscale, PD = power Doppler, US = ultrasonography.
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tolerated during any disease course among patients with RA
receiving biological/targeted synthetic DMARDs.
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